Tag: cannabinoid pharmaceutical R&D
AusCann raises A$33.4m via share placement
ASX-listed medical marijuana company AusCann has successfully raised A$33.4 million via a share placement to institutional and sophisticated investors from North America and Australia, including...
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
